Trospium chloride for the treatment of overactive bladder with urge incontinence

Clinical Therapeutics

Volumn 27, Issue 5, 2005, Pages 511-530

  Singh Franco, Devada ^a   Machado, Caridad ^a   Tuteja, Sony ^a   Zapantis, Antonia ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Trospium; Trospium and oxybutynin; Trospium and pharmacokinetics; Trospium and placebo; Trospium and tolterodine; Urinary incontinence

Indexed keywords

ANTIFUNGAL AGENT; BETHANECHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; DICYCLOVERINE; DIGOXIN; DOXAZOSIN; DOXEPIN; ESTROGEN; FINASTERIDE; HYOSCYAMINE; IMIPRAMINE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OXYBUTYNIN; PLACEBO; PRAZOSIN; PROCAINAMIDE; PROPANTHELINE BROMIDE; PSEUDOEPHEDRINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; WATER;

ABDOMINAL PAIN; AGITATION; AGRANULOCYTOSIS; ANAPHYLAXIS; ATRIOVENTRICULAR BLOCK; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER FILLING; BLADDER PRESSURE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CYSTOMETRY; DELIRIUM; DETRUSOR MUSCLE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TOLERABILITY; DRY EYE; DYSPEPSIA; ECG ABNORMALITY; ERYTHEMA; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HOT FLUSH; HUMAN; HYDROLYSIS; HYPOSALIVATION; INTRAOCULAR HYPERTENSION; KIDNEY FAILURE; KIDNEY TUBULE EXCRETION; LETHARGY; LEUKOPENIA; LIVER DYSFUNCTION; MEDICAL LITERATURE; MICTURITION; NEUROGENIC BLADDER; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; OXIDATION; PARALYTIC ILEUS; PATHOPHYSIOLOGY; PRURITUS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SOMNOLENCE; SPINAL CORD INJURY; ST SEGMENT DEPRESSION; STEVENS JOHNSON SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; SYMPTOM; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

AGING; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; CRESOLS; FEMALE; HUMANS; KIDNEY FAILURE; LIVER FAILURE; MALE; MANDELIC ACIDS; METABOLIC CLEARANCE RATE; NORTROPANES; PHENYLPROPANOLAMINE; RANDOMIZED CONTROLLED TRIALS; URINARY INCONTINENCE;

EID: 20644457700     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.05.008     Document Type: Review

References (58)

1. Abrams P, Cardozo L, and Fall M The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. de Groat WC A neurologic basis for the overactive bladder Urology 50 Suppl 6A 1997 36 52
3. 2.gif&imgrefurl=http://www.classes.kumc.edu/som/amed900/incontinence/ incon
4. Flynn R Structure and function in continence and incontinence Lucas M Emery S Beynon J Incontinence 1999 Blackwell Science Ltd Oxford, UK 12 44
5. Shah J, and Leach G Anatomy and physiology Urinary Incontinence 2nd ed. 2001 Health Press Oxford, UK 7 10
6. Dorey G Urinary continence Conservative Treatment of Male Urinary Incontinence and Erectile Dysfunction 2001 Whurr Publishers Philadelphia, Pa 21 28
7. Rovner ES, Wyman J, and Lackner T Urinary incontinence DiPiro JT Talbert RL Yee GC Pharmacotherapy, A Pathophysiologic Approach 5th ed. 2002 McGraw-Hill New York 1543 1556
8. Lee M Management of benign prostatic hyperplasia DiPiro JT Talbert TL Yee GC Pharmacotherapy. A Pathophysiologic Approach 5th ed. 2002 McGraw-Hill New York 1533 1542
9. Hu T, Wagner TH, and Bentkover JD Costs of urinary incontinence and overactive bladder in the United States: A comparative study Urology 63 2004 461 465
10. Jackson RA, Vittinghoff E, and Kanaya AM Urinary incontinence in elderly women: Findings from the Health, Aging, and Body Composition Study Obstet Gynecol 104 2004 301 307
11. Hunskaar S, Lose G, Sykes D, and Voss S The prevalence of urinary incontinence in women in four European countries BJU Int 93 2004 324 330
12. Thom D Variation in estimates of urinary incontinence prevalence in the community: Effects of differences in definition, population characteristics, and study type J Am Geriatr Soc 46 1998 473 480
13. Melville JL, Walker E, and Katon W Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence Am J Obstet Gynecol 187 2002 80 87
14. Aggazzotti G, Pesce F, and Grassi D Prevalence of urinary incontinence among institutionalized patients: A cross-sectional epidemiologic study in a midsized city in northern Italy Urology 56 2000 245 249
15. Andersson KE Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53
16. Propantheline bromide McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 1180 1188
17. Propantheline bromide McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 1206 1207
18. Scopolamine hydrobromide McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 1207 1211
19. Imipramine hydrochloride McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 2125 2133
20. Imipramine hydrochloride McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 2147 2148
21. Doxepine hydrochloride McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 2125 2133
22. Doxepine hydrochloride McEvoy GK AHFS Drug Information 2001 American Society of Health-System Pharmacists Bethesda, Md 2146 2147
23. Ditropan [package insert]. Palo Alto, Calif: ALZA Corporation; 1999.
24. Ditropan XL [package insert]. Mountain View, Calif: ALZA Corporation; 2004.
25. Oxytrol [package insert]. Corona, Calif: Watson Laboratories; 2003.
26. Detrol [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn; 1998.
27. Detrol LA [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn; 2004.
28. Sanctura [package insert]. Troisdorf, Germany: Madaus AG; 2004.
29. Ditropan XL (ALZA Corporation) oxybutynin XL. Cardinal Health product description. Available at Accessed September 14, 2004
30. Detrol (Pharmacia & Upjohn) tolerodine. Cardinal Health product description. Available at Accessed September 14, 2004
31. Sanctura (Madaus AG) trospium chloride. Cardinal Health product description. Available at Accessed September 14, 2004
32. Malone-Lee J, Shaffu B, Amand C, and Powell C Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial J Urol 165 2001 1452 1456
33. Diokno AC, Appell RA, and Sand PK Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial Mayo Clin Proc 78 2003 687 695
34. for the Transdermal Oxybutynin Study Group Dmochowski RR, Sand PK, and Zinner NR Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 62 2003 237 242
35. Langguth P, Kubis A, and Krumbiegel G Intestinal absorption of the quaternary trospium chloride: Permeability-lowering factors and bioavailabilities from oral dosage forms Eur J Pharm Biopharm 43 1997 265 272
36. Schröder S, Jetter A, and Zaigler M Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration Int J Clin Pharmacol Ther 42 2004 543 549
37. Abstract 687 Zerres K, Zaigler M, and Reitbrock S Pharmacokinetics of single- and multiple-dose trospium chloride in elderly volunteers using a replicative design Naunyn Schmiedebergs Arch Pharmacol 357 Suppl 4 1998 R175
38. Todorova A, Vonderheid-Guth B, and Dimpfel W Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system J Clin Pharmacol 41 2001 636 644
39. Pietzko A, Dimpfel W, Schwantes U, and Topfmeier P Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers Eur J Clin Pharmacol 47 1994 337 343
40. Pak RW, Petrou SP, and Staskin DR Trospium chloride: A quaternary amine with unique pharmacologic properties Curr Urol Rep 4 2003 436 440
41. Uckert S, Stief CG, and Odenthal KP Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder Arzneimittelforschung 50 2000 456 460
42. Schladitz-Keil G, Spahn H, and Mutschler E Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data Arzneimittelforschung 36 1986 984 987
43. Paris, France. Abstract 584 Sandage B, Najarian N, and Lasseter K The effect of hepatic disease on the pharmacokinetics of trospium chloride Program and abstracts of the Annual Meeting of the International Continence Society August 23-27 2004
44. Guay DR Clinical pharmacokinetics of drugs used to treat urge incontinence Clin Pharmacokinet 42 2003 1243 1285
45. Rovner ES Trospium chloride in the management of overactive bladder Drugs 64 2004 2433 2446
46. Bauer LA Clinical pharmacokinetic and pharmacodynamic concepts Applied Clinical Pharmacokinetics 2001 McGraw-Hill New York 3 25
47. Bauer LA Clinical pharmacokinetic equations and calculations Applied Clinical Pharmacokinetics 2001 McGraw-Hill New York 26 49
48. Beckmann-Knopp S, Rietbrock S, and Weyhenmeyer R Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes Pharmacol Toxicol 85 1999 299 304
49. Stöhrer M, Bauer P, and Giannetti BM Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial Urol Int 47 1991 138 143
50. Alloussi S, Laval KU, and Eckert R Trospium chloride (Spasmo-lyt®) in patients with motor urge syndrome (detrusor instability): Double-blind, randomized, placebo-controlled study J Drug Assess 2 1999 27 39
51. Cardozo L, Chapple CR, and Toozs-Hobson M Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind, multicentre clinical trial BJU Int 85 2000 659 664
52. Zinner N, Gittelman M, and Harris R Trospium chloride improves overactive bladder symptoms: A multicenter Phase III trial J Urol 171 2004 2311 2315
53. Florence, Italy. Abstract 119 Bowden A, Colman S, and Sabounjian L Psychometric validation of an urgency severity scale (IUSS) for patients with overactive bladder Program and abstracts of the Annual Meeting of the International Continence Society October 5-9 2003
54. for the Continence Program in Women (CPW) Research Group Shumaker SA, Wyman JF, and Uebersax JS Health-related quality of life measures for women with urinary incontinence: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory Qual Life Res 3 1994 291 306
55. Madersbacher H, Stöhrer M, and Richter R Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia Br J Urol 75 1995 452 456
56. Halaska M, Ralph G, and Wiedemann A Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability World J Urol 20 2003 392 399
57. Abstract Junemann KP, and Al-Shukri S Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: A double-blind, placebo-controlled, multicenter clinical trial Neurourol Urodyn 19 2000 85B
58. Frohlich G, Bulitta M, and Strosser W Trospium chloride in patients with detrusor overactivity: Meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily Int J Clin Pharmacol Ther 40 2002 295 303